IDEAYA Biosciences, Inc.
IDYA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001676725
In the last 90 days, IDEAYA Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 285 institutions reported holding it in 13F filings for Q2 2026, worth $3.81B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $382.1K in total
- 1
- 13F holdersQ2 2026, +33 vs. previous quarter
- 285
- 13F valueReported value at the end of Q2 2026
- $3.81B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IDYA, Q2 2026
No superinvestor reported holding IDYA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by IDEAYA Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 (view filing)4:56 PM ET | Jul 7 | 2 days | Ruiz Briseno AndresChief Accounting Officer | SSale | −9.55K | $40.01 | −$382.1K | −26.5%26.5K after | 10b5-1 |
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Stein JeffreyDirector | PPurchase | +50.0K | $32.96 | +$1.65M | +1,168.0%54.3K after | |
| May 31, 2024 (view filing) | May 29 | 2 days | White Michael AnthonyChief Scientific Officer | SSale | −28.5K | $36.25 | −$1.03M | −100.0%0 after | 2 lots10b5-1 |
| May 16, 2024 (view filing) | May 14-16 | 2 days | Hata Yujiro SPresident and CEO | SSale | −175.0K | $42.27 | −$7.40M | −20.5%677.9K after | 7 lots10b5-1 |
| Feb 13, 2024 (view filing) | Feb 9 | 4 days | Ruiz Briseno AndresSee Remarks | SSale | −2.00K | $46.02 | −$92.0K | −7.5%24.5K after | 10b5-1 |
| Feb 12, 2024 (view filing) | Feb 8-9 | 4 days | Hata Yujiro SPresident and CEO | SSale | −99.4K | $45.24 | −$4.50M | −12.8%677.9K after | 2 lots10b5-1 |
| Feb 5, 2024 (view filing) | Feb 1 | 4 days | Hata Yujiro SPresident and CEO | SSale | −628 | $45.00 | −$28.3K | −0.1%677.9K after | 2 lots10b5-1 |
| Jan 24, 2024 (view filing) | Jan 22 | 2 days | Ruiz Briseno AndresSee Remarks | SSale | −2.00K | $42.03 | −$84.1K | −7.0%26.5K after | 10b5-1 |
| Jan 17, 2024 (view filing) | Jan 12 | 5 days | Ruiz Briseno AndresSee Remarks | SSale | −2.00K | $38.01 | −$76.0K | −6.6%28.5K after | 10b5-1 |
| Jan 17, 2024 (view filing) | Jan 12-16 | 5 days | Hata Yujiro SPresident and CEO | SSale | −75.0K | $40.15 | −$3.01M | −10.0%677.9K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in IDEAYA Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 14,109,431 | $525.9M | 0.02% | +937,328+7.1% | Added |
| BlackRock, Inc. | 8,893,260 | $331.5M | 0.00% | +451,127+5.3% | Added |
| Jupiter Topco LLC | 8,579,881 | $319.7M | 0.13% | +8,579,881 | New |
| Capital Research Global Investors | 5,344,701 | $199.2M | 0.03% | +181,158+3.5% | Added |
| Baker Bros. Advisors LP | 5,010,030 | $186.7M | 0.94% | +1,063,515+26.9% | Added |
| State Street Corp | 4,548,911 | $169.5M | 0.01% | +767,744+20.3% | Added |
| Vanguard Capital Management LLC | 4,132,646 | $154.0M | 0.00% | +400,224+10.7% | Added |
| Logos Global Management LP | 3,000,000 | $111.8M | 4.81% | −450,000−13.0% | Reduced |
| Adage Capital Partners GP, L.L.C. | 2,715,391 | $101.2M | 0.14% | −108,109−3.8% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 2,714,503 | $101.2M | 1.06% | +1,184,495+77.4% | Added |